AU2013311025A1 - Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir - Google Patents
Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir Download PDFInfo
- Publication number
- AU2013311025A1 AU2013311025A1 AU2013311025A AU2013311025A AU2013311025A1 AU 2013311025 A1 AU2013311025 A1 AU 2013311025A1 AU 2013311025 A AU2013311025 A AU 2013311025A AU 2013311025 A AU2013311025 A AU 2013311025A AU 2013311025 A1 AU2013311025 A1 AU 2013311025A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- hcv
- iii
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12182551.7 | 2012-08-31 | ||
| EP12182551 | 2012-08-31 | ||
| EP12185890 | 2012-09-25 | ||
| EP12185890.6 | 2012-09-25 | ||
| PCT/IB2013/058138 WO2014033668A2 (en) | 2012-08-31 | 2013-08-30 | Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013311025A1 true AU2013311025A1 (en) | 2015-02-26 |
Family
ID=49920362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013311025A Abandoned AU2013311025A1 (en) | 2012-08-31 | 2013-08-30 | Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150209366A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2890378A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015526504A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150046083A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104780921A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013311025A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015003913A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2881052A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL237049A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015002684A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015111491A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014033668A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
| CN106727516A (zh) * | 2017-01-10 | 2017-05-31 | 山东省立医院 | 一种治疗丙型肝炎的药物组合物 |
| WO2020001814A1 (en) | 2018-06-27 | 2020-01-02 | Robert Bosch Gmbh | Method for operating a hybrid powertrain with an electric machine, an internal combustion engine and a variable transmission |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作c型肝炎病毒抑制劑之巨環吲哚衍生物 |
| SMT201700121T1 (it) * | 2009-02-27 | 2017-03-08 | Janssen Pharmaceuticals Inc | Sale amorfo di un inibitore macrociclico di hcv |
| MX2012011963A (es) * | 2010-04-13 | 2012-12-17 | Janssen Pharmaceuticals Inc | Combinacion de un inhibidor macrociclico del virus de la hepatitis c, un no-nucleosido y un nucleosido. |
-
2013
- 2013-08-30 JP JP2015529186A patent/JP2015526504A/ja active Pending
- 2013-08-30 BR BR112015003913A patent/BR112015003913A2/pt not_active IP Right Cessation
- 2013-08-30 WO PCT/IB2013/058138 patent/WO2014033668A2/en not_active Ceased
- 2013-08-30 CN CN201380045145.7A patent/CN104780921A/zh active Pending
- 2013-08-30 KR KR1020157005596A patent/KR20150046083A/ko not_active Withdrawn
- 2013-08-30 EP EP13818373.6A patent/EP2890378A2/en not_active Withdrawn
- 2013-08-30 CA CA2881052A patent/CA2881052A1/en not_active Abandoned
- 2013-08-30 MX MX2015002684A patent/MX2015002684A/es unknown
- 2013-08-30 US US14/422,005 patent/US20150209366A1/en not_active Abandoned
- 2013-08-30 AU AU2013311025A patent/AU2013311025A1/en not_active Abandoned
- 2013-08-30 RU RU2015111491A patent/RU2015111491A/ru not_active Application Discontinuation
-
2015
- 2015-02-02 IL IL237049A patent/IL237049A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014033668A2 (en) | 2014-03-06 |
| WO2014033668A3 (en) | 2014-05-01 |
| CA2881052A1 (en) | 2014-03-06 |
| JP2015526504A (ja) | 2015-09-10 |
| BR112015003913A2 (pt) | 2017-07-04 |
| US20150209366A1 (en) | 2015-07-30 |
| KR20150046083A (ko) | 2015-04-29 |
| MX2015002684A (es) | 2015-05-12 |
| RU2015111491A (ru) | 2016-10-20 |
| IL237049A0 (en) | 2015-03-31 |
| EP2890378A2 (en) | 2015-07-08 |
| CN104780921A (zh) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110171174A1 (en) | Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside | |
| JP6043338B2 (ja) | 抗ウイルス治療用の1’−置換ピリミジンn−ヌクレオシド類似体 | |
| WO2010031832A9 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
| EP3848026A1 (en) | Combinations and methods comprising a capsid assembly inhibitor | |
| KR20180058828A (ko) | Hbv 캡시드 조립 억제제와 인터페론의 조합 치료 | |
| JP2008530124A (ja) | フラビウイルス感染症を処置または予防するための組成物および方法 | |
| JP2013521279A (ja) | Hcv複製の阻害剤としての医薬併用剤 | |
| TW201306839A (zh) | 治療hcv感染之組合療法 | |
| CA2881052A1 (en) | Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir | |
| AU2011239974B2 (en) | Combination of a macrocyclic inhibitor of HCV, a non-nucleoside and a nucleoside | |
| Tidwong et al. | Pharmacological treatment for the Novel Coronavirus disease 2019 (COVID-19 Infection) | |
| JP2017514834A (ja) | Hcv感染症を治療するための組合せ療法 | |
| HK1161833A (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and nucleoside | |
| HK1180222B (en) | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside | |
| CN101014341A (zh) | 治疗或预防嗜肝dna病毒科病毒感染的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |